文献速递药物相互作用

处方大麻二酚治疗癫痫发作的初始药物相互作用管理:专科药师的作用

Prescription cannabidiol for seizure disorder management: Initial drug-drug interaction management by specialty pharmacists.
PubMed 文献 · Am J Health Syst Pharm · 2022-01-01

本研究为单中心回顾性研究,纳入2019年1月至2020年4月某医疗中心神经科门诊因癫痫管理而处方大麻二酚(CBD)的患者136例。结果显示80%的患者在基线时存在药物相互作用(DDI),共260项,其中71%为药效学相互作用、29%为药代动力学相互作用;管理方式以仅咨询为主(89%),其次为停用相互作用药物(9%)和调整相互作用药物剂量(2%)。氯巴占是最常见的相互作用药物(24%),丙戊酸占10%。研究提示整合专科药师在识别和管理处方CBD初始DDI中可发挥重要作用。

要点

  • 80%的患者在启动处方CBD时存在至少一项DDI,以药效学相互作用为主。
  • 氯巴占是最常见相互作用药物(24%),其次为丙戊酸(10%)。
  • 多数DDI通过药师咨询即可管理,少数需停药或调整剂量。

核心结论

  • 整合专科药师可在识别和管理处方CBD初始DDI中发挥重要作用。

研究设计与样本

  • 单中心回顾性研究,纳入2019年1月至2020年4月神经科门诊处方CBD用于癫痫管理的患者136例。

主要发现

  • 109例(80%)在基线时存在DDI,共260项。
  • 260项DDI中,药效学相互作用占71%(n=184),药代动力学相互作用占29%(n=76)。
  • DDI管理方式:仅咨询占89%(n=232项),停用相互作用药物占9%(n=22项),调整相互作用药物剂量占2%(n=6项)。
  • 氯巴占是最常见相互作用药物(n=63,24%),丙戊酸占10%(n=26)。
  • 人群以白人(n=115,85%)、18岁及以下(n=92,68%)、Lennox-Gastaut综合征(n=117,86%)为主。

临床怎么用

  • 处方CBD启动治疗时,专科药师应系统筛查DDI,尤其关注氯巴占和丙戊酸等常见相互作用药物。
  • 多数DDI可通过患者咨询管理,部分需停用或调整相互作用药物剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the presence, type, and management of drug-drug interactions (DDIs) at prescription cannabidiol (CBD) therapy initiation. METHODS: We conducted a single-center, retrospective study of patients prescribed CBD from a medical center's neurology clinic for seizure management from January 2019 through April 2020. Patients were excluded if they were enrolled in a CBD clinical trial or the insurance approval or medication fulfillment process was not completed by the center's specialty pharmacy. The primary outcomes were the numbers, types, and management of DDIs identified at the time of CBD prescribing. RESULTS: Of the 136 patients included, 109 (80%) had a DDI identified at baseline. Of the 260 DDIs, 71% (n = 184) were pharmacodynamic and 29% (n = 76) were pharmacokinetic in nature. Management of the 260 DDIs detected included counseling only (89% [n = 232 interactions]), discontinuation of the interacting agent [9% (n = 22 interactions]), and dosage change for the interacting agent [2% (n = 6 interactions]). Clobazam was the most commonly identified interacting medication (n = 63, 24%), while valproic acid accounted for 10% (n = 26) of the DDIs. The population was predominantly white (n = 115, 85%), 18 years of age or younger (n = 92, 68%), and had an indication for prescription CBD treatment of Lennox-Gastaut syndrome (n = 117, 86%). CONCLUSION: This study provides new information on the role that integrated specialty pharmacists can play in identifying and managing initial DDIs in patients starting prescription CBD.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Dial H, Owens W, DeClercq J, et al. Prescription cannabidiol for seizure disorder management: Initial drug-drug interaction management by specialty pharmacists. Am J Health Syst Pharm. 2022. PMID: 35675751. doi:10.1093/ajhp/zxac155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。